ERBB2 and breast cancer: Schlam et al. (2021) used it to profile the TME of primary and metastatic HER2+ breast cancer [18], discovering differences in immune cell infiltration and the expression of immune activation markers, with primary tumors showing enhanced immune cell infiltration within the stromal compartment compared with metastatic disease.